Skip to content

Clinical outcomes of adjunctive antimicrobial photodynamic therapy in the treatment of patients with severe chronic periodontitis - a controlled randomized clinical trial

Clinical outcomes of adjunctive antimicrobial photodynamic therapy in the treatment of patients with severe chronic periodontitis - a controlled randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00005389
Enrollment
45
Registered
2014-03-21
Start date
2009-11-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe chronic periodontitis K05.3

Interventions

Group 1: control group: scaling and root debridement Group 2: test group 1: scaling and root debridement plus adjunctive phododynamic therapy treatments (immediately after scaling and root debrideme

Sponsors

Danube Private University (DPU)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: - age of 30–70 years - present diagnosis of severe chronic periodontitis of at least 6 teeth with a probing pocket depth (PPD) >5 mm, bleeding - written informed consent - Plaque Index (PI) < 1 and Gingiva Index (GI) <1 after pretreatment

Exclusion criteria

Exclusion criteria: - major systemic illnesses (i.e., diabetes mellitus, cancer, HIV, tuberculosis, bone metabolic diseases or disorders that compromise wound healing, rheumatoid arthritis, lupus erythematosus) - radiation, or immunosuppressive therapy - pregnant or breastfeeding woman - smoking behaviour - use of long-term administration of anti-inflammatory medications - antibiotic therapies in the previous 6 months - teeth with furcation involvement - radiologically diagnosted combined endodontic-periodontic lesions

Design outcomes

Primary

MeasureTime frame
probing pocket depth, measured with computer administrated probe (Florida-Probe) at baseline, as well as 3, 6 and 12 months after therapy

Secondary

MeasureTime frame
Bleeding on Probing (number of sites with bleeding after Probing) measured with computer adnmistraded probe at baseline, 3, 6 and 12 months after therapy, periodontopathogenic bacteria measured with a chairside test at baseline, 2 weeks, 6 and 12 months after therapy, inflammatory markers from gingival cevicular fluid

Countries

Germany

Contacts

Public ContactDaniela Hoedke

Charité Universitätsmedizin BerlinCC3 ZahnklinikAbteilung für Parodontologie und synoptische Zahnmedizin

daniela.hoedke@charite.de004930450562334

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026